The prognostic significance of circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide and neuron- specific enolase in patients with advanced non-small-cell lung cancer Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
Chemerin and PAI-1 activity as diagnostic biomarkers in resectable NSCLC:comparison to classic tumour markers Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019
Importance of tumour markers CYFRA 21-1 and NSE serum concentration values in diagnosis and esteem of nonmicrocelullar lung cancer expansion Source: Eur Respir J 2005; 26: Suppl. 49, 325s Year: 2005
MonoTotal vs. other cytokeratin markers in NSCLC Source: Annual Congress 2008 - Various aspects of thoracic oncology Year: 2008
Post operative dynamism of NSCLC tumor markers (CEA, CYFRA 21.1, NSE, TK, TPS) Source: Eur Respir J 2006; 28: Suppl. 50, 719s Year: 2006
Neuron-specific enolase (NSE) serum level as a prognostic factor for tumor regression and survival in non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 73s Year: 2002
Clinical correlates and prognostic significance of neuron specific enolase (NSE) in non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 73s Year: 2002
Serum neuron-specific enolase - a marker for disease extent and response to therapy of small-cell lung cancerSource: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004
The diagnostic value of serum tumor markers in newly diagnosed lung cancer patients Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017
Serum napsin A is a novel diagnostic and monitoring marker for interstitial lung disease Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease Year: 2011
Role of progestrin releasing peptide (ProGRP), a serum based biomarker in early diagnosis of SCLC in cohort of high-risk patient presenting with symptoms related to lung cancer Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
The diagnostic value of the examination of the tumor markers CYFRA 21-1, NSE, TPA and CEA from the bronchoalveolar lavage fluid in diffuse pulmonary disorders Source: Annual Congress 2008 - Role of bronchoalveolar lavage in studying the pathophysiology of interstitial lung disease Year: 2008
Clinical contribution of tumor marker CYFRA 21-1 in evaluation of response to therapy in NSCLC patients Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001
Soluble mesothelin as an early diagnostic tool in asbestos-exposed workers Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience Year: 2009
MAdL: A new diagnostic marker for adenocarcinomas Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
Soluble mesothelin as a monitoring tool for malignant mesothelioma patients Source: Annual Congress 2009 - New insights in biology and treatment of pleural tumours Year: 2009
Biodynamic approach to pretreatment level of tumor marker CYFRA 21-1 in differential diagnosis of single pulmonary nodules Source: Annual Congress 2003 - Early lung cancer diagnosis Year: 2003
Diagnostic utility of CYFRA 21-1 and carcinoembryonic antigen as a tumour markers in malignant pleural effusions Source: Eur Respir J 2001; 18: Suppl. 33, 397s Year: 2001
Usefulness of determination of tumour markers TPA and cyfra 21.1 in follow up study after radical therapy in patients with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001
Serum carcinoembryonic antigen (CEA) level as a predictive marker for distant metastasis in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 85s Year: 2006